Literature DB >> 23306613

c-Cbl shRNA-expressing adenovirus sensitizes TRAIL-induced apoptosis in prostate cancer DU-145 through increases of DR4/5.

S Y Kim1, J-H Kim, J J Song.   

Abstract

We previously demonstrated that the downregulation of Casitas B-lineage lymphoma (c-Cbl) can sensitize tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in two different ways. One way is to block the rapid degradation of TRAIL receptors, which can sustain TRAIL-induced apoptosis for a long time. Here, we designed a replication-defective adenovirus expressing the short hairpin RNA (shRNA) against c-Cbl to test the possibility of developing a cancer gene therapy that can act as a sensitizer of TRAIL. As expected from the results of our previous study that used a stable cell line with downregulated c-Cbl, infection with the c-Cbl shRNA-expressing adenovirus led to an increase in the death receptor 4 (DR4) and DR5 levels, which is known to be a cause for the increase of TRAIL-induced apoptosis. In conclusion, we demonstrated that c-Cbl shRNA-expressing adenovirus is able to sensitize TRAIL-induced apoptosis in vivo as well as in vitro.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23306613     DOI: 10.1038/cgt.2012.88

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  11 in total

1.  Four Immune Modulating Genes in Primary Melanoma That Predict Metastatic Potential.

Authors:  Jennifer Erdrich; Kristel Lourdault; Alex Judd; David Kaufman; Ke Wei Gong; Melanie Gainsbury; Nan Deng; Wonwoo Shon; Richard Essner
Journal:  J Surg Res       Date:  2022-08-05       Impact factor: 2.417

2.  DR4-Associated Death Receptor Signal Promotes Cartilage Damage in Patients With Kashin-Beck Disease.

Authors:  Shixun Wu; Zhi Yi; Ming Ling; Shizhang Liu; Zhengming Sun; Xiong Guo
Journal:  Cartilage       Date:  2019-11-24       Impact factor: 3.117

3.  Chloroquine enhances TRAIL-mediated apoptosis through up-regulation of DR5 by stabilization of mRNA and protein in cancer cells.

Authors:  Eun Jung Park; Kyoung-jin Min; Kyeong Sook Choi; Peter Kubatka; Peter Kruzliak; Dong Eun Kim; Taeg Kyu Kwon
Journal:  Sci Rep       Date:  2016-03-11       Impact factor: 4.379

4.  c-CBL regulates melanoma proliferation, migration, invasion and the FAK-SRC-GRB2 nexus.

Authors:  Minakshi Nihal; Gary S Wood
Journal:  Oncotarget       Date:  2016-08-16

5.  In Vitro and In Vivo Efficacy Studies of Lavender angustifolia Essential Oil and Its Active Constituents on the Proliferation of Human Prostate Cancer.

Authors:  Yunqi Zhao; Ran Chen; Yun Wang; Chen Qing; Wei Wang; Yixin Yang
Journal:  Integr Cancer Ther       Date:  2016-05-05       Impact factor: 3.279

6.  The proteasome deubiquitinase inhibitor b-AP15 enhances DR5 activation-induced apoptosis through stabilizing DR5.

Authors:  You-Take Oh; Liang Deng; Jiusheng Deng; Shi-Yong Sun
Journal:  Sci Rep       Date:  2017-08-14       Impact factor: 4.379

7.  Understanding of tolerance in TRAIL-induced apoptosis and cancelation of its machinery by α-mangostin, a xanthone derivative.

Authors:  Minami Kumazaki; Haruka Shinohara; Kohei Taniguchi; Hiroshi Ueda; Mayuko Nishi; Akihide Ryo; Yukihiro Akao
Journal:  Oncotarget       Date:  2015-09-22

8.  MicroRNA-155 regulates the proliferation, cell cycle, apoptosis and migration of colon cancer cells and targets CBL.

Authors:  Hua Yu; Weiling Xu; Fangchao Gong; Baorong Chi; Junyi Chen; Ling Zhou
Journal:  Exp Ther Med       Date:  2017-08-31       Impact factor: 2.447

9.  Involvement of Up-Regulation of DR5 Expression and Down-Regulation of c-FLIP in Niclosamide-Mediated TRAIL Sensitization in Human Renal Carcinoma Caki Cells.

Authors:  Jeong Mi Yun; Seon Min Woo; Seung Un Seo; Kyoung-Jin Min; Dong Eun Kim; Taeg Kyu Kwon
Journal:  Molecules       Date:  2018-09-05       Impact factor: 4.411

10.  Inflammatory bowel disease-associated ubiquitin ligase RNF183 promotes lysosomal degradation of DR5 and TRAIL-induced caspase activation.

Authors:  Yan Wu; Yuka Kimura; Takumi Okamoto; Koji Matsuhisa; Rie Asada; Atsushi Saito; Fumika Sakaue; Kazunori Imaizumi; Masayuki Kaneko
Journal:  Sci Rep       Date:  2019-12-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.